Another Funding Win For Chiesi In Europe As Scotland OKs Elfabrio

Scotland’s health technology assessment body has agreed to reimburse Chiesi’s Elfabrio for Fabry disease, mirroring the decision from several other European countries – however, France turned down the rare disease drug, while Germany questioned its benefit.

Thumbs Up
• Source: Shutterstock

More from Health Technology Assessment

More from Market Access